Simon Collett, Linda Earnest, Julio Carrera Montoya, Melissa A Edeling, Ashley Yap, Chinn Yi Wong, Dale Christiansen, Jason Roberts, Jamie Mumford, Valerie Lecouturier, Vincent Pavot, Sergio Marco, Joon Keit Loi, Cameron Simmons, Shivali A Gulab, Jason M Mackenzie, Aaron Elbourne, Paul A Ramsland, Garth Cameron, Dhiraj Hans, Dale I Godfrey, Joseph Torresi
The development of virus-like particle (VLP) based vaccines for human papillomavirus, hepatitis B and hepatitis E viruses represented a breakthrough in vaccine development. However, for dengue and COVID-19, technical complications, such as an incomplete understanding of the requirements for protective immunity, but also limitations in processes to manufacture VLP vaccines for enveloped viruses to large scale, have hampered VLP vaccine development. Selecting the right adjuvant is also an important consideration to ensure that a VLP vaccine induces protective antibody and T cell responses...
2023: Frontiers in Microbiology